244 related articles for article (PubMed ID: 25296971)
21. Dasatinib, a Src inhibitor, sensitizes liver metastatic colorectal carcinoma to oxaliplatin in tumors with high levels of phospho-Src.
Perez M; Lucena-Cacace A; Marín-Gómez LM; Padillo-Ruiz J; Robles-Frias MJ; Saez C; Garcia-Carbonero R; Carnero A
Oncotarget; 2016 May; 7(22):33111-24. PubMed ID: 27105527
[TBL] [Abstract][Full Text] [Related]
22. Gossypol sensitizes the antitumor activity of 5-FU through down-regulation of thymidylate synthase in human colon carcinoma cells.
Yang D; Qu J; Qu X; Cao Y; Xu L; Hou K; Feng W; Liu Y
Cancer Chemother Pharmacol; 2015 Sep; 76(3):575-86. PubMed ID: 26208739
[TBL] [Abstract][Full Text] [Related]
23. Synergy between histone deacetylase inhibitors and DNA-damaging agents is mediated by histone deacetylase 2 in colorectal cancer.
Alzoubi S; Brody L; Rahman S; Mahul-Mellier AL; Mercado N; Ito K; El-Bahrawy M; Silver A; Boobis A; Bell JD; Hajji N
Oncotarget; 2016 Jul; 7(28):44505-44521. PubMed ID: 27283986
[TBL] [Abstract][Full Text] [Related]
24. Overcoming acquired BRAF inhibitor resistance in melanoma via targeted inhibition of Hsp90 with ganetespib.
Acquaviva J; Smith DL; Jimenez JP; Zhang C; Sequeira M; He S; Sang J; Bates RC; Proia DA
Mol Cancer Ther; 2014 Feb; 13(2):353-63. PubMed ID: 24398428
[TBL] [Abstract][Full Text] [Related]
25. Combined 5-FU and ChoKα inhibitors as a new alternative therapy of colorectal cancer: evidence in human tumor-derived cell lines and mouse xenografts.
de la Cueva A; Ramírez de Molina A; Alvarez-Ayerza N; Ramos MA; Cebrián A; Del Pulgar TG; Lacal JC
PLoS One; 2013; 8(6):e64961. PubMed ID: 23762272
[TBL] [Abstract][Full Text] [Related]
26. E2F1/TS Immunophenotype and Survival of Patients with Colorectal Cancer Treated with 5FU-Based Adjuvant Therapy.
Sulzyc-Bielicka V; Domagala P; Bielicki D; Safranow K; Rogowski W; Domagala W
Pathol Oncol Res; 2016 Jul; 22(3):601-8. PubMed ID: 26831819
[TBL] [Abstract][Full Text] [Related]
27. Ginsenoside Rg3 targets cancer stem cells and tumor angiogenesis to inhibit colorectal cancer progression in vivo.
Tang YC; Zhang Y; Zhou J; Zhi Q; Wu MY; Gong FR; Shen M; Liu L; Tao M; Shen B; Gu DM; Yu J; Xu MD; Gao Y; Li W
Int J Oncol; 2018 Jan; 52(1):127-138. PubMed ID: 29115601
[TBL] [Abstract][Full Text] [Related]
28. Association between ERCC1 and TS mRNA levels and disease free survival in colorectal cancer patients receiving oxaliplatin and fluorouracil (5-FU) adjuvant chemotherapy.
Li S; Zhu L; Yao L; Xia L; Pan L
BMC Gastroenterol; 2014 Aug; 14():154. PubMed ID: 25175730
[TBL] [Abstract][Full Text] [Related]
29. DJ‑1 is a new prognostic marker and predicts chemotherapy efficacy in colorectal cancer.
Wang W; Wang H; Xiang L; Ni T; Jin F; Deng J; Zhang Y; Shintaro I; Zhou Y; Liu Y
Oncol Rep; 2020 Jul; 44(1):77-90. PubMed ID: 32627002
[TBL] [Abstract][Full Text] [Related]
30. Network analysis identifies an HSP90-central hub susceptible in ovarian cancer.
Liu H; Xiao F; Serebriiskii IG; O'Brien SW; Maglaty MA; Astsaturov I; Litwin S; Martin LP; Proia DA; Golemis EA; Connolly DC
Clin Cancer Res; 2013 Sep; 19(18):5053-67. PubMed ID: 23900136
[TBL] [Abstract][Full Text] [Related]
31. Acquired resistance to 5-fluorouracil via HSP90/Src-mediated increase in thymidylate synthase expression in colon cancer.
Ahn JY; Lee JS; Min HY; Lee HY
Oncotarget; 2015 Oct; 6(32):32622-33. PubMed ID: 26416450
[TBL] [Abstract][Full Text] [Related]
32. The sirtuin inhibitor tenovin-6 upregulates death receptor 5 and enhances cytotoxic effects of 5-fluorouracil and oxaliplatin in colon cancer cells.
Ueno T; Endo S; Saito R; Hirose M; Hirai S; Suzuki H; Yamato K; Hyodo I
Oncol Res; 2013; 21(3):155-64. PubMed ID: 24512730
[TBL] [Abstract][Full Text] [Related]
33. Ursolic acid synergistically enhances the therapeutic effects of oxaliplatin in colorectal cancer.
Shan J; Xuan Y; Zhang Q; Zhu C; Liu Z; Zhang S
Protein Cell; 2016 Aug; 7(8):571-85. PubMed ID: 27472952
[TBL] [Abstract][Full Text] [Related]
34. Combining trail with PI3 kinase or HSP90 inhibitors enhances apoptosis in colorectal cancer cells via suppression of survival signaling.
Saturno G; Valenti M; De Haven Brandon A; Thomas GV; Eccles S; Clarke PA; Workman P
Oncotarget; 2013 Aug; 4(8):1185-98. PubMed ID: 23852390
[TBL] [Abstract][Full Text] [Related]
35. MEK inhibitor enhanced the antitumor effect of oxaliplatin and 5‑fluorouracil in MEK1 Q56P‑mutant colorectal cancer cells.
Jing C; Li H; Du Y; Cao H; Liu S; Wang Z; Ma R; Feng J; Wu J
Mol Med Rep; 2019 Feb; 19(2):1092-1100. PubMed ID: 30535504
[TBL] [Abstract][Full Text] [Related]
36. Efficacy of an HSP90 inhibitor, ganetespib, in preclinical thyroid cancer models.
Lin SF; Lin JD; Hsueh C; Chou TC; Yeh CN; Chen MH; Wong RJ
Oncotarget; 2017 Jun; 8(25):41294-41304. PubMed ID: 28476040
[TBL] [Abstract][Full Text] [Related]
37. MicroRNA-375-3p enhances chemosensitivity to 5-fluorouracil by targeting thymidylate synthase in colorectal cancer.
Xu F; Ye ML; Zhang YP; Li WJ; Li MT; Wang HZ; Qiu X; Xu Y; Yin JW; Hu Q; Wei WH; Chang Y; Liu L; Zhao Q
Cancer Sci; 2020 May; 111(5):1528-1541. PubMed ID: 32073706
[TBL] [Abstract][Full Text] [Related]
38. Antiproliferative effects of ZD0473 (AMD473) in combination with 5-fluorouracil or SN38 in human colorectal cancer cell lines.
Plasencia C; Abad A; Martinez-Balibrea E; Taron M
Invest New Drugs; 2004 Nov; 22(4):399-409. PubMed ID: 15292710
[TBL] [Abstract][Full Text] [Related]
39. Activity of the heat shock protein 90 inhibitor ganetespib in melanoma.
Wu X; Marmarelis ME; Hodi FS
PLoS One; 2013; 8(2):e56134. PubMed ID: 23418523
[TBL] [Abstract][Full Text] [Related]
40. Blocking heat shock protein-90 inhibits the invasive properties and hepatic growth of human colon cancer cells and improves the efficacy of oxaliplatin in p53-deficient colon cancer tumors in vivo.
Moser C; Lang SA; Kainz S; Gaumann A; Fichtner-Feigl S; Koehl GE; Schlitt HJ; Geissler EK; Stoeltzing O
Mol Cancer Ther; 2007 Nov; 6(11):2868-78. PubMed ID: 18025273
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
